Page 2 - Divi's Laboratories

At Rs 58.8 cr, Murali of Divi's Lab highest paid pharma honcho in FY19

According to Divis latest annual report, Murali Divi, the promoter-executive,was given a hike of 46.3 per cent in his remuneration over the previous fiscal

Income-Tax department raids drug firm Divi's Laboratories premises

The company said the raids were conducted by the officials of Income-Tax Department under Section 132 of the Income-Tax Act

Divi's Labs hits new high; soars 26% in three weeks on strong Q2 results

The stock hit a new high of Rs 1,574, up 3% on the BSE today.

With revenues, profit set to increase, re-rating ahead for Divi's Labs

Analysts have upgraded estimates on supply disruption, weak rupee

Divi's Labs gains 4% on successful USFDA inspection of Telangana unit

The stock was up 4% to Rs 1,213 on the BSE in early morning deal, trading close to its 52-week high of Rs 1,220 touched on May 11, 2018.

Divi's Laboratories Vizag unit receives USFDA EIR with six observations

The USFDA releases a copy of the EIR to the establishment that was the subject of an FDA inspection

Divi's Labs surges 21% as USFDA to lift import alert for Visakhapatnam unit

The stock surged 21% to Rs 1,117 on the BSE in early morning trade on back of nearly four-fold jump in trading volumes.

Divi's Labs surges 6% on successful USFDA inspection of Unit-2

The stock trading at its highest level since December 23, 2016, has outperformed the market by surging 47% in past one month, as compared to 4% rise in Sensex.

Divi's Laboratories: High on hopes

Positive outcome of ongoing plant inspection can lead to more gains

Divi's Lab shares down nearly 5%, profits falls 41% in Q1

Company has posted a net profit of Rs 301.81 crore for corresponding period of previous fiscal

Divis Labs hits 52-week low

In past six months, the stock slipped 52% as compared to 4% rise in the S&P BSE Sensex.

Divi's Labs' Vizag unit gets warning letter from USFDA

BS Reporter Hyderabad, 22 AprilDivi'sLaboratories has informed the stock exchanges that the US drug regulator hasissued a warning letter for its unit-II at Visakhapatnam, Andhra Pradesh. "We willrespond to this warning letter with a detailed plan within the stipulated time,"the company said in a statement on Saturday, without disclosing the details ofthe warning letter.Divi's Labs,along with external consultants and subject matter experts, is working toaddress the concerns of the US Food and Drug Administration (US FDA) and ismaking all efforts to fully meet the compliance requirements, it said. The USFDA hadearlier had issued a form 483 with five observations after inspected the Visakhapatnamunit from November 29, 2016 to December 6, 2016. Divi's has respondedto the observations with an appropriate remediation process to overcome thedeficiencies observed, and also provided periodic updates to the agency. However, theregulator has issued an import alert on March 20 on the products ...

Divi's weighs share buyback following sharp fall in share price

Hyderabad, 27 March: Divis Laboratories Limited management on Monday said buy back of shares using the cash reserves could be an option in the light of a sharp fall in the company's share price though its current focus was on the remedial steps at Unit 2, which received an import alert by the US Food and Drug Administration(USFDA) last week."Yes, this is an option(that can be looked into)," the company's founder and chairman Murali K Divi said in response to a suggestion if Divis would consider using the free cash, amounting to Rs 1,700 crore, for share buyback as the share price corrected quite a bit, touching the 52 week low on the day the news was broke about the import alert.Responding to analyst queries in a conference call organised on the regulatory setback faced by the Visakhaptnam facility, which accounts for 65 percent of the total sales revenues of the company, Murali said they have no clue as to why the US FDA has directly announced an import alert without issuing a ...

USFDA adds one more clause to import alert on Divi's Labs

BS ReporterHyderabad, 22 March: The US Food and Drug Administration(US FDA) has invoked one more clause with regard to the import alert issued to Unit-2 of Hyderabad-based Divis Laboratories Limited, this time charging the company with 'refusal for inspection'.The import alert was first issued under clause 66-40, which authorises detention without physical examination of drugs from firms that have not met drug GMPs (good manufacturing practices). Further, the US drug regulator has added clause 99-32, which authorises a similar action for products from firms reusing 'FDA foreign establishment inspection.'While admitting the development in a disclosure to Bombay Stock Exchange(BSE) on Wednesday, the company management, however, did not explain the reasons leading to the invocation of clause 99-32 by the US regulator.Meanwhile the previous records show that in August 2016 the 'Divi Towers', which is the company's headquarters in Hyderabad and an Active Pharmaceutical Ingredients (API) ...

Divi's Labs: Uncertainties remain despite good Q3

Divi's maintained its FY17 guidance of 15% revenue growth with EBITDA margin of about 38%

Divi's Lab standalone Q3 net up 9% at Rs 268 crore

Income from operations uo 14% to Rs 976 cr; however, nine-month profit is flat at Rs 792 cr

Divi's Labs standalone Q3 net up 9% at Rs 268 cr

Total income from operations rose 13.5% to Rs 976.48 crore during the quarter

Divi's shares partly recover from the recent lows

After steep hit in two trading sessions, shares recovered with a 3.08% increase at Rs 788.9

One-third of Divi's scrip value melts down in two sessions

Possible import alert after USFDA remarks about firm's Vizag unit drags stock down to two-year low

Divi's scrip falls 21% on FDA remarks

USFDA observed that its Vizag facility was not maintained to ensure the quality of the APIs